/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology firm that discovers, develops, and commercializes transformative medicines for serious diseases, with a particular focus on treatments for cystic fibrosis and other genetic disorders. The company’s product portfolio includes several approved therapies, such as Trikafta/Kaftrio, and emerging drugs for conditions like sickle cell disease and acute pain, supported by a robust clinical pipeline across multiple therapeutic areas. Vertex is headquartered in Boston, Massachusetts. Its market cap is about $124.8 billion, reflecting its status as one of the larger biotech stocks.
Shares of the company have underperformed the broader market over the past 52 weeks. VRTX has gained 6.3% over this time frame, while the broader S&P 500 Index ($SPX) has gained 11.8%. However, the stock has risen 8.4% on a YTD basis, outperforming SPX’s marginal decline.
